Has Luis Tejada, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,351 in general payments to Luis Tejada, MD across 33 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Luis Tejada, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Luis Tejada, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Luis Tejada, MD

Interventional Cardiology · Bethlehem, PANPI 1295707628

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Abbott at 27.3% of the total. 2025 is the largest year on record at $432, more than ten times the $18 reported in 2019. That places this record below the midpoint for interventional cardiology clinicians in PA, where the typical reported total is $6,486.

$1,351in general payments, 2019–2025

Across 33 payments — averaging $40.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$369
Edwards Lifesciences$320
Shockwave Medical, Inc$148
Abiomed$123
Boehringer Ingelheim$116
Insulet Corporation$84
plus $191 from 6 others

$76,992in research payments, 2019–2025

Across 59 payments — averaging $1304.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Janssen Research & Development, LLC$55K
Daiichi Sankyo Inc.$22K

What the payments were for

Food & beverage$1,351100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	8	$369
Edwards Lifesciences	5	$320
Shockwave Medical, Inc	7	$148
Abiomed	1	$123
Boehringer Ingelheim	2	$116
Insulet Corporation	2	$84
Boston Scientific	2	$53
Chiesi USA, Inc.	2	$49
E.r. Squibb & Sons, L.L.C.	1	$28
Medtronic	1	$22
Biotronik Inc.	1	$21
Terumo Medical Corporation	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

SAPIEN 3 Ultra RESILIA$145
COROFLOW$140
Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$134
Impella$123
OPTIS$112

How this compares

$1,351 in reported general payments places this provider in the 10th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$141,697

Medicare patients

513

Services billed

1,137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	282	$281,701
XareltoRivaroxaban	130	$106,215
Repatha SureclickEvolocumab	27	$30,985
EntrestoSacubitril/Valsartan	24	$23,648
BrilintaTicagrelor	20	$16,298
Praluent PenAlirocumab	25	$15,872
Metoprolol Succinate	428	$6,291
Ranolazine ErRanolazine	66	$5,828
Atorvastatin Calcium	524	$5,354
ClopidogrelClopidogrel Bisulfate	253	$2,855
Metoprolol Tartrate	357	$2,407
Flecainide Acetate	36	$2,105
Isosorbide Mononitrate ErIsosorbide Mononitrate	120	$1,832
Rosuvastatin Calcium	141	$1,632
Dofetilide	14	$1,554

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Bethlehem

Nishant SethiScranton$1.3M
Matthew BeckerErie$1M
William GrayWynnewood$753K
Jon GeorgePhiladelphia$637K
Shailendra SinghAllentown$470K
Sanjog KalraPhiladelphia$444K
James HarveyChambersburg$442K
Taisei KobayashiPhiladelphia$384K
Antonis PratsosBroomall$377K
Ronald FieldsNew Hope$373K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →